文献速递心力衰竭与心肌病冠心病血脂与心血管预防

螺内酯对心力衰竭高风险人群心血管功能及纤维化标志物的影响:HOMAGE随机临床试验

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
PubMed 文献 · Eur Heart J · 2021-01-01

HOMAGE随机开放标签盲终点试验纳入527例冠心病或高危且B型利钠肽升高者,比较螺内酯50 mg/日与对照最长9个月。主要终点基线血清半乳糖凝集素-3与Ⅲ型前胶原氨基端前肽变化的交互作用未达显著,但螺内酯组Ⅰ型前胶原羧基端前肽及PICP/CITP比值显著降低,收缩压、左房容积和NT-proBNP亦下降。

要点

  • 螺内酯未通过半乳糖凝集素-3识别胶原标志物更大降幅。
  • 螺内酯显著降低PICP及PICP/CITP比值,可能影响Ⅰ型胶原代谢。
  • 螺内酯降低收缩压、左房容积和NT-proBNP,能否延缓症状性心衰待研究。

核心结论

  • 半乳糖凝集素-3未能识别螺内酯应答中胶原标志物更大降幅的人群。
  • 螺内酯可能影响Ⅰ型胶原代谢,并降低收缩压、左房容积和NT-proBNP。
  • 螺内酯能否延缓或预防进展为症状性心衰尚需进一步研究。

研究设计与样本

  • 随机、开放标签、盲终点试验,比较螺内酯50 mg/日或对照最长9个月。
  • 纳入患有冠心病或高危且血浆B型利钠肽升高者,共527例,中位年龄73岁,女性26%。

主要发现

  • PIIINP变化在螺内酯组与对照组相似(平均差-0.15;95%CI -0.44至0.15 μg/L;P=0.32)。
  • 螺内酯组PICP降幅更大(平均差-8.1;95%CI -11.9至-4.3 μg/L;P<0.0001)。
  • 螺内酯组PICP/CITP比值降幅更大(平均差-2.9;95%CI -4.3至-1.5;P<0.0001)。
  • 未观察到与血清半乳糖凝集素-3的交互作用。
  • 螺内酯组收缩压(平均差-10;95%CI -13至-7 mmHg;P<0.0001)、左房容积(平均差-1;95%CI -2至0 mL/m2;P=0.010)和NT-proBNP(平均差-57;95%CI -81至-33 ng/L;P<0.0001)降低。

临床怎么用

  • 对于冠心病或高危且利钠肽升高者,螺内酯可能改善Ⅰ型胶原代谢相关标志物。
  • 螺内酯可降低收缩压、左房容积和NT-proBNP,但延缓症状性心衰的获益尚未证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. METHODS AND RESULTS: Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or control for up to 9 months in people with, or at high risk of, coronary disease and raised plasma B-type natriuretic peptides. The primary endpoint was the interaction between baseline serum galectin-3 and changes in serum procollagen type-III N-terminal pro-peptide (PIIINP) in participants assigned to spironolactone or control. Procollagen type-I C-terminal pro-peptide (PICP) and collagen type-1 C-terminal telopeptide (CITP), reflecting synthesis and degradation of type-I collagen, were also measured. In 527 participants (median age 73 years, 26% women), changes in PIIINP were similar for spironolactone and control [mean difference (mdiff): -0.15; 95% confidence interval (CI) -0.44 to 0.15 μg/L; P = 0.32] but those receiving spironolactone had greater reductions in PICP (mdiff: -8.1; 95% CI -11.9 to -4.3 μg/L; P < 0.0001) and PICP/CITP ratio (mdiff: -2.9; 95% CI -4.3 to -1.5; <0.0001). No interactions with serum galectin were observed. Systolic blood pressure (mdiff: -10; 95% CI -13 to -7 mmHg; P < 0.0001), left atrial volume (mdiff: -1; 95% CI -2 to 0 mL/m2; P = 0.010), and NT-proBNP (mdiff: -57; 95% CI -81 to -33 ng/L; P < 0.0001) were reduced in those assigned spironolactone. CONCLUSIONS: Galectin-3 did not identify greater reductions in serum concentrations of collagen biomarkers in response to spironolactone. However, spironolactone may influence type-I collagen metabolism. Whether spironolactone can delay or prevent progression to symptomatic heart failure should be investigated.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Cleland JGF, Ferreira JP, Mariottoni B, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021. PMID: 33215209. doi:10.1093/eurheartj/ehaa758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。